Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting

Why is the Fed concerned about the housing market? How did Trump's Intel investment impact the chipmaker? What caused the recent stock rally after Powell's speech? Why did European postal services suspend US shipments? How is Trump influencing Federal Reserve governance? What are the implications of the Texas redistricting plan? Why is the Trump administration halting offshore wind projects?

Biohaven Advances Toward Potential First FDA-Approved Therapy For Spinocerebellar Ataxia, FDA Drops Advisory Meeting

benzinga.com/news/fda/25/08/47280567/biohaven-advances-toward-potential-first-fda-approved-therapy-for-spinocerebellar-ataxia-fda-drops-advis

Biohaven Ltd. (NYSE:BHVN) stock is trading higher on Friday following an update with respect to its New Drug Application for troriluzole for adult patients with Spinocerebellar Ataxia (SCA).
In May 2025, the Division of Neurology 1 within the Office of Neuroscience of the Food and Drug…

This story appeared on benzinga.com, 2025-08-22 13:14:12.